- Home
- GYRE vs THRM Comparison
GYRE vs THRM Comparison
Compare GYRE & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- THRM
- Stock Information
- Founded
- GYRE 2002
- THRM 1991
- Country
- GYRE United States
- THRM United States
- Employees
- GYRE N/A
- THRM N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- THRM Auto Parts:O.E.M.
- Sector
- GYRE Health Care
- THRM Consumer Discretionary
- Exchange
- GYRE Nasdaq
- THRM Nasdaq
- Market Cap
- GYRE 897.1M
- THRM 997.7M
- IPO Year
- GYRE N/A
- THRM 1993
- Fundamental
- Price
- GYRE $7.71
- THRM $36.32
- Analyst Decision
- GYRE Strong Buy
- THRM Buy
- Analyst Count
- GYRE 1
- THRM 3
- Target Price
- GYRE $18.00
- THRM $46.00
- AVG Volume (30 Days)
- GYRE 86.3K
- THRM 217.5K
- Earning Date
- GYRE 08-11-2025
- THRM 10-29-2025
- Dividend Yield
- GYRE N/A
- THRM N/A
- EPS Growth
- GYRE N/A
- THRM N/A
- EPS
- GYRE 0.02
- THRM 1.02
- Revenue
- GYRE $102,189,000.00
- THRM $1,453,370,000.00
- Revenue This Year
- GYRE $21.04
- THRM $1.64
- Revenue Next Year
- GYRE $89.64
- THRM $3.31
- P/E Ratio
- GYRE $454.38
- THRM $36.16
- Revenue Growth
- GYRE N/A
- THRM N/A
- 52 Week Low
- GYRE $6.11
- THRM $22.75
- 52 Week High
- GYRE $19.00
- THRM $51.00
- Technical
- Relative Strength Index (RSI)
- GYRE 49.56
- THRM 62.59
- Support Level
- GYRE $7.61
- THRM $34.63
- Resistance Level
- GYRE $8.40
- THRM $35.88
- Average True Range (ATR)
- GYRE 0.47
- THRM 0.85
- MACD
- GYRE 0.01
- THRM -0.00
- Stochastic Oscillator
- GYRE 34.29
- THRM 68.54
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About THRM Gentherm Inc
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.